Immix Biopharma today reported positive study data for its lead candidate, IMX-110. The study, which was conducted in soft tissue sarcoma, achieved a 50% response rate, which is significantly higher than the standard of care for this cancer. ImmixBio reports that its lead candidate, IMX-110, exhibited significant activity in a first-line-therapy resistant model of soft tissue sarcoma. The data reinforced the company’s strategy to develop SMARxT-based therapeutics that are unique in their approach to addressing challenging conditions.
The US Food and Drug Administration approved IMX-109 for the treatment of soft tissues sarcoma. This approval is in addition to the agency’s approval of rare pediatric disease selection for the same disease. Immix Biopharma has shared data from its ongoing clinical program for IMX-109 in heavily pretreated patients with advanced soft tissue sarcoma. These data show that the treatment led to a median progression-free survival of 4 months. Soft tissue sarcoma is a type of cancer that appears in the tissues that encircle the body. It is estimated that the global market for this disease will reach over $6.5 billion by 2030. According to the American Cancer Society, around 13,000 new cases of STS were diagnosed in the US in 2020.